NeuroVive: "TBI Miracle Drug" profiled in US pharmaceutical magazine

Lund, Sweden - September 15, 2011 - A U.S. magazine called Pharmaceutical Formulation & Quality (circulation to 20,000 senior pharmaceutical executives throughout the US and Canada) has just published an article explaining cyclosporine and its potential as a traumatic brain injury (TBI) pharmaceutical. The article, entitled "Cyclosporine - TBI's Miracle Drug," is in the magazine's August/September 2011 issue. Subtitled: "An accidental discovery about 20 years ago has led to a cyclosporine pharmaceutical on the threshold of approval". The article explains the history of NeuroVive's initial research and the reasons why cyclosporine has such positive impact on TBI and reperfusion injury in myocardial infarction. The article can be read online at the magazine's website (www.pharmaquality.com).

The article was authored by Steve Campbell, a writer and communication consultant in Vancouver, B.C., who writes for and about pharmaceutical and scientific research, products, and biotech companies. NeuroVive´s CSO Eskil Elmér reviewed the article to ensure scientific accuracy.

About NeuroVive
NeuroVive Pharmaceutical AB is a Swedish drug development company whose primary mission is to develop drugs for the treatment of acute brain injury, reperfusion injury in myocardial infarction and other acute injuries where mitochondrial energy production is critical for clinical outcome. The research and development program focuses on developing new variants of cyclophilin-D-inhibiting cyclosporins and studying ways of transporting these drugs across the blood-brain barrier to the central nervous system.

NeuroVive´s shares are listed on the Swedish trading platform AktieTorget (www.aktietorget.se). The AktieTorget market is focused on emerging, entrepreneurial businesses through an electronic trading system supplied by the OMX Nordic stock exchange in Stockholm, Sweden.


For further information contact:
Mikael Brönnegård, MD, CEO, NeuroVive Pharmaceutical AB
Telephone: +46 46 288 0110
Cell: +46 70 299 6264
E-mail: mikael.bronnegard@neurovive.com
Web: www.neurovive.com 
Biomedical Center BMC D10, SE-221 84 Lund, Sweden

About Us

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for chronic treatment of primary mitochondrial diseases and one project, in preparation for clinical trials (NV354), for treatment of primary mitochondrial diseases with Complex I deficiency. NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study. The R&D portfolio also consists of early projects for primary mitochondrial disease, and NASH. NeuroVive’s ambition is to take drugs for primary mitochondrial diseases through clinical development and all the way to market, with or without partners. For the TBI and NASH projects the goal is to enter strategic partnerships. A subset of compounds under NeuroVive’s NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber’s Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF). www.neurovive.com

Subscribe

Documents & Links